Company Profile
Sight Sciences Stock Price, News & Catalysts
- Ticker:
- SGHT
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United States
Stock performance
8.08 USD (-0.74%)
Close
Last updated: September 17, 2026
236M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, SGHT closed down 0.74% at $8.08. No new same-company headline was identified in the current news window.
Company overview
Interventional Eye Care
Sight Sciences develops minimally invasive and noninvasive technologies intended to address underlying causes of glaucoma and dry-eye disease.
Glaucoma Systems
OMNI and OMNI Edge are implant-free minimally invasive glaucoma-surgery systems that access Schlemm's canal and the trabecular meshwork. SION is a bladeless device used to excise trabecular meshwork.
TearCare
TearCare applies localized heat to the eyelids so physicians can clear obstructed meibomian glands, addressing a major cause of evaporative dry-eye disease.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Sight Sciences (SGHT)?
Sight Sciences (SGHT) most recently closed at 8.08 USD, a -0.74% move versus the previous session.
What is the market cap of Sight Sciences (SGHT)?
Sight Sciences currently has a market capitalization of 236M USD on BioPharmSignal.
What does Sight Sciences do?
Interventional Eye Care Sight Sciences develops minimally invasive and noninvasive technologies intended to address underlying causes of glaucoma and dry-eye disease. Glaucoma Systems OMNI and OMNI Edge are implant-free minimally invasive glaucoma-surgery systems that access Schlemm's canal and the trabecular meshwork. SION is a bladeless device used to...
On which exchange is SGHT stock listed?
Sight Sciences (SGHT) is associated with NASDAQ, United States, MedTech.
What is Interventional?
Interventional Eye Care Sight Sciences develops minimally invasive and noninvasive technologies intended to address underlying causes of glaucoma and dry-eye disease.
Which conditions is Sight Sciences targeting with Interventional?
Interventional Eye Care Sight Sciences develops minimally invasive and noninvasive technologies intended to address underlying causes of glaucoma and dry-eye disease. Glaucoma Systems OMNI and OMNI Edge are implant-free minimally invasive glaucoma-surgery systems that access Schlemm's canal and the trabecular meshwork. SION is a bladeless device used to...
What is Care?
Interventional Eye Care Sight Sciences develops minimally invasive and noninvasive technologies intended to address underlying causes of glaucoma and dry-eye disease.
What is Sight?
Interventional Eye Care Sight Sciences develops minimally invasive and noninvasive technologies intended to address underlying causes of glaucoma and dry-eye disease.